High-dose tobramycin inhibits lipopolysaccharide-induced MUC5AC production in human lung epithelial cells

European Journal of Pharmacology

Volumn 659, Issue 1, 2011, Pages 67-71

  Nakamura, Shigeki ^a   Yanagihara, Katsunori ^a   Araki, Nobuko ^a   Yamada, Koichi ^a   Morinaga, Yoshitomo ^a   Izumikawa, Koichi ^a   Seki, Masafumi ^a   Kakeya, Hiroshi ^a   Yamamoto, Yoshihiro ^a   Kamihira, Shimeru ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Bronchial cell; High dose tobramycin; Lipopolysaccharide; Mitogen activated protein kinase pathway; MUC5AC; Pseudomonas aeruginosa

Indexed keywords

DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MUCIN 5AC; TOBRAMYCIN;

ARTICLE; CELL ACTIVATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE REPRESSION; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS INHIBITION; PSEUDOMONAS AERUGINOSA; SIGNAL TRANSDUCTION; BIOSYNTHESIS; CELL LINE; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; LUNG; METABOLISM; PHOSPHORYLATION;

CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; LIPOPOLYSACCHARIDES; LUNG; MITOGEN-ACTIVATED PROTEIN KINASES; MUCIN 5AC; NF-KAPPA B; PHOSPHORYLATION; RNA, MESSENGER; TOBRAMYCIN;

EID: 79958812434     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.03.002     Document Type: Article

References (39)

1. Anderson, G.G., Moreau-Marquis, S., Stanton, B.A., O'Toole, G.A., 2008. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect. Immun. 76, 1423-1433.
2. Bilton, D., Henig, N., Morrissey, B., Gotfried, M., 2006. Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 130, 1503-1510. (Pubitemid 44786746)
3. Dabbagh, K., Takeyama, K., Lee, H.M., Ueki, I.F., Lausier, J.A., Nadel, J.A., 1999. IL-4 induces mucin gene expression and goblet cell metaplasia in vitro and in vivo. J. Immunol. 162, 6233-6237. (Pubitemid 29314987)
4. Dal Negro, R., Micheletto, C., Tognella, S., Visconti, M., Turati, C., 2008. Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation. Adv. Ther. 25, 1019-1030.
5. Davies, J.R., Svitacheva, N., Lannefors, L., Kornfalt, R., Carlstedt, I., 1999. Identification of MUC5B, MUC5AC and small amounts of MUC2 mucins in cystic fibrosis airway secretions. Biochem. J. 344 (Pt 2), 321-330. (Pubitemid 30011586)
6. Dohrman, A., Miyata, S., Gallup, M., Li, J.D., Chapelin, C., Coste, A., Escudier, E., Nadel, J., Basbaum, C., 1998. Mucin gene (MUC 2 and MUC 5AC) upregulation by Gram-positive and Gram-negative bacteria. Biochim. Biophys. Acta 1406, 251-259.
7. Drobnic, M.E., Sune, P., Montoro, J.B., Ferrer, A., Orriols, R., 2005. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann. Pharmacother. 39, 39-44.
8. Du, M., Jones, J.R., Lanier, J., Keeling, K.M., Lindsey, J.R., Tousson, A., Bebok, Z., Whitsett, J.A., Dey, C.R., Colledge, W.H., Evans, M.J., Sorscher, E.J., Bedwell, D.M., 2002. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J. Mol. Med. 80, 595-604.
9. Fitzgerald, J.E., King Jr., T.E., Lynch, D.A., Tuder, R.M., Schwarz, M.I., 1996. Diffuse panbronchiolitis in the United States. Am. J. Respir. Crit. Care Med. 154, 497-503.
10. Geller, D.E., Pitlick, W.H., Nardella, P.A., Tracewell, W.G., Ramsey, B.W., 2002. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122, 219-226. (Pubitemid 34754166)
11. Gendler, S.J., Spicer, A.P., 1995. Epithelial mucin genes. Annu. Rev. Physiol. 57, 607-634.
12. Ghannam, D.E., Rodriguez, G.H., Raad, I.I., Safdar, A., 2009. Inhaled aminoglycosides in cancer patients with ventilator-associated Gram-negative bacterial pneumonia: safety and feasibility in the era of escalating drug resistance. Eur. J. Clin. Microbiol. Infect. Dis. 28, 253-259.
13. Gibson, R.L., Burns, J.L., Ramsey, B.W., 2003a. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918-951.
14. Gibson, R.L., Emerson, J., McNamara, S., Burns, J.L., Rosenfeld, M., Yunker, A., Hamblett, N., Accurso, F., Dovey, M., Hiatt, P., Konstan, M.W., Moss, R., Retsch-Bogart, G., Wagener, J., Waltz, D., Wilmott, R., Zeitlin, P.L., Ramsey, B., 2003b. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am. J. Respir. Crit. Care Med. 167, 841-849.
15. Hasegawa, H., Yamada, Y., Komiyama, K., Hayashi, M., Ishibashi, M., Yoshida, T., Sakai, T., Koyano, T., Kam, T.S., Murata, K., Sugahara, K., Tsuruda, K., Akamatsu, N., Tsukasaki, K., Masuda, M., Takasu, N., Kamihira, S., 2006. Dihydroflavonol BB-1, an extract of natural plant Blumea balsamifera, abrogates TRAIL resistance in leukemia cells. Blood 107, 679-688. (Pubitemid 43076394)
16. Hovenberg, H.W., Davies, J.R., Herrmann, A., Linden, C.J., Carlstedt, I., 1996. MUC5AC, but not MUC2, is a prominent mucin in respiratory secretions. Glycoconj. J. 13, 839-847. (Pubitemid 26354277)
17. Hunt, B.E., Weber, A., Berger, A., Ramsey, B., Smith, A.L., 1995. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob. Agents Chemother. 39, 34-39.
18. Husson, M.O., Wizla-Derambure, N., Turck, D., Gosset, P., Wallaert, B., 2005. Effect of intermittent inhaled tobramycin on sputum cytokine profiles in cystic fibrosis. J. Antimicrob. Chemother. 56, 247-249.
19. Imamura, Y., Yanagihara, K., Mizuta, Y., Seki, M., Ohno, H., Higashiyama, Y., Miyazaki, Y., Tsukamoto, K., Hirakata, Y., Tomono, K., Kadota, J., Kohno, S., 2004. Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-Oxododecanoyl) homoserine lactone in NCI-H292 cells. Antimicrob. Agents Chemother. 48, 3457-3461.
20. Ishimoto, H., Mukae, H., Sakamoto, N., Amenomori, M., Kitazaki, T., Imamura, Y., Fujita, H., Ishii, H., Nakayama, S., Yanagihara, K., Kohno, S., 2009. Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin. J. Antimicrob. Chemother. 63, 109-114.
21. Kaneko, Y., Yanagihara, K., Seki, M., Kuroki, M., Miyazaki, Y., Hirakata, Y., Mukae, H., Tomono, K., Kadota, J., Kohno, S., 2003. Clarithromycin inhibits overproduction of muc5ac core protein in murine model of diffuse panbronchiolitis. Am. J. Physiol. Lung Cell. Mol. Physiol. 285, L847-L853.
22. Kawai, T., Akira, S., 2005. Pathogen recognition with Toll-like receptors. Curr. Opin. Immunol. 17, 338-344.
23. Kim, Y.D., Kwon, E.J., Park, D.W., Song, S.Y., Yoon, S.K., Baek, S.H., 2002. Interleukin-1beta induces MUC2 and MUC5AC synthesis through cyclooxygenase-2 in NCI-H292 cells. Mol. Pharmacol. 62, 1112-1118.
24. Landry, R.M., An, D., Hupp, J.T., Singh, P.K., Parsek, M.R., 2006. Mucin-Pseudomonas aeruginosa interactions promote biofilm formation and antibiotic resistance. Mol. Microbiol. 59, 142-151.
25. Li, J.D., Dohrman, A.F., Gallup, M., Miyata, S., Gum, J.R., Kim, Y.S., Nadel, J.A., Prince, A., Basbaum, C.B., 1997. Transcriptional activation of mucin by Pseudomonas aeruginosa lipopolysaccharide in the pathogenesis of cystic fibrosis lung disease. Proc. Natl Acad. Sci. U.S.A. 94, 967-972.
26. Longphre, M., Li, D., Gallup, M., Drori, E., Ordonez, C.L., Redman, T., Wenzel, S., Bice, D.E., Fahy, J.V., Basbaum, C., 1999. Allergen-induced IL-9 directly stimulates mucin transcription in respiratory epithelial cells. J. Clin. Invest. 104, 1375-1382.
27. Medzhitov, R., 2001. Toll-like receptors and innate immunity. Nat. Rev. Immunol. 1, 135-145.
28. Mohr, A.M., Sifri, Z.C., Horng, H.S., Sadek, R., Savetamal, A., Hauser, C.J., Livingston, D.H., 2007. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia. Surg. Infect. Larchmt. 8, 349-357.
29. Naber, K.G., Westenfelder, S.R., Madsen, P.O., 1973. Pharmacokinetics of the aminoglycoside antibiotic tobramycin in humans. Antimicrob. Agents Chemother. 3, 469-473.
30. Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J., Vasiljev, K.M., Borowitz, D., Bowman, C.M., Marshall, B.C., Marshall, S., Smith, A.L., 1999. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med. 340, 23-30.
31. Ratjen, F., Doring, G., Nikolaizik, W.H., 2001. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet 358, 983-984. (Pubitemid 32913526)
32. Scheinberg, P., Shore, E., 2005. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 127, 1420-1426. (Pubitemid 46224309)
33. Shim, J.J., Dabbagh, K., Ueki, I.F., Dao-Pick, T., Burgel, P.R., Takeyama, K., Tam, D.C., Nadel, J.A., 2001. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am. J. Physiol. Lung Cell. Mol. Physiol. 280, L134-L140.
34. Singh, P.K., Schaefer, A.L., Parsek, M.R., Moninger, T.O., Welsh, M.J., Greenberg, E.P., 2000. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407, 762-764.
35. Takeyama, K., Dabbagh, K., Jeong Shim, J., Dao-Pick, T., Ueki, I.F., Nadel, J.A., 2000. Oxidative stress causes mucin synthesis via transactivation of epidermal growth factor receptor: role of neutrophils. J. Immunol. 164, 1546-1552. (Pubitemid 30067272)
36. Takeyama, K., Dabbagh, K., Lee, H.M., Agusti, C., Lausier, J.A., Ueki, I.F., Grattan, K.M., Nadel, J.A., 1999. Epidermal growth factor system regulates mucin production in airways. Proc. Natl Acad. Sci. U.S.A. 96, 3081-3086.
37. Tamaoki, J., Takeyama, K., Yamawaki, I., Kondo, M., Konno, K., 1997. Lipopolysaccharide-induced goblet cell hypersecretion in the guinea pig trachea: inhibition bymacrolides. Am. J. Physiol. 272, L15-L19.
38. Touw, D.J., Jacobs, F.A., Brimicombe, R.W., Heijerman, H.G., Bakker, W., Briemer, D.D., 1997. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 41, 184-187.
39. Yanagihara, K., Seki, M., Cheng, P.W., 2001. Lipopolysaccharide induces mucus cell metaplasia in mouse lung. Am. J. Respir. Cell Mol. Biol. 24, 66-73.